Randomized Trial Assessing the Significance of Bevacizumab in Recurrent Grade II and Grade III Gliomas - The TAVAREC Trial

Trial Profile

Randomized Trial Assessing the Significance of Bevacizumab in Recurrent Grade II and Grade III Gliomas - The TAVAREC Trial

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Oct 2016

At a glance

  • Drugs Bevacizumab (Primary) ; Temozolomide (Primary)
  • Indications Astrocytoma; Glioma; Oligodendroglioma
  • Focus Therapeutic Use
  • Acronyms TAVAREC
  • Most Recent Events

    • 11 Oct 2016 Planned primary completion date changed from 1 Jul 2016 to 1 Jun 2017.
    • 01 Sep 2016 Planned number of patients changed from 144 to 155.
    • 16 Jul 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top